NCT00756509View on ClinicalTrials.gov

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 29, 2008

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Nilotinib

800 mg/d orally

Trial Locations (7)

15526

Novartis Investigative Site, Bad Saarow

20133

Novartis Investigative Site, Milan

30625

Novartis Investigative Site, Hanover

45147

Novartis Investigative Site, Essen

69373

Novartis Investigative Site, Lyon

81377

Novartis Investigative Site, München

FIN-00029

Novartis Investigative Site, Helsinki

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY